Loading
A phase 3 trial of Tunlametinib run by Shanghai Kechow Pharma, Inc. in melanoma, now recruiting.
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma is a phase 3 interventional study registered as NCT06008106 by Shanghai Kechow Pharma, Inc., with 165 participants planned, started 2023-11-02. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Kechow Pharma, Tunlametinib, Small-molecule kinase inhibitors.
Shares Acral melanoma, Mucosal melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Acral melanoma, Mucosal melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/